
Regeneron Pharmaceuticals (REGN) Stock Forecast & Price Target
Regeneron Pharmaceuticals (REGN) Analyst Ratings
Bulls say
Regeneron Pharmaceuticals is a company with a strong portfolio of marketed products and a promising pipeline targeting various diseases. Despite recent setbacks in clinical trials, the company's continued growth and strong partnerships with companies like Sanofi and Bayer indicate a positive outlook for future developments. Additionally, the company shows a commitment to sustainability and diversity, which could further bolster its reputation and success in the long run. With strategic collaborations and a diverse product portfolio, Regeneron shows potential for significant growth and potential in the biopharmaceutical industry.
Bears say
Regeneron Pharmaceuticals is facing short-term pressure, driven by the concentration of investor activity ahead of a recent readout. While the company has strong partnerships and commercial products, issues with a recent trial may hinder its pipeline potential. The company has also faced pricing and market share loss concerns for its main product, Eylea, and may see continued pressure in the near term unless significant external developments occur.
This aggregate rating is based on analysts' research of Regeneron Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Regeneron Pharmaceuticals (REGN) Analyst Forecast & Price Prediction
Start investing in Regeneron Pharmaceuticals (REGN)
Order type
Buy in
Order amount
Est. shares
0 shares